Related Experiment Video

Updated: Dec 15, 2025

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.4K

Isorhamnetin induces the paraptotic cell death through ROS and the ERK/MAPK pathway in OSCC cells

Qian Chen1, Shaojuan Song1, Zhen Wang1

  • 1State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, Sichuan University, Chengdu, China.

Oral Diseases
|July 13, 2020
PubMed
Abstract

Insights

Isorhamnetin effectively inhibits oral squamous cell carcinoma (OSCC) growth by inducing paraptosis, a distinct form of cell death. This finding suggests isorhamnetin as a potential therapeutic agent for OSCC treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Oral squamous cell carcinoma (OSCC) remains a significant health concern with limited therapeutic options.
  • Investigating novel compounds like isorhamnetin for anti-cancer properties is crucial.

Purpose of the Study:

  • To evaluate the anti-cancer effects of isorhamnetin on OSCC cells.
  • To elucidate the molecular mechanisms underlying isorhamnetin's action.

Main Methods:

  • OSCC cells were treated with isorhamnetin.
  • Assessed were cell proliferation, cell cycle, migration, and cell death.
  • Related signaling pathways, including ERK, were analyzed.

Main Results:

  • Isorhamnetin inhibited OSCC cell proliferation and viability in a dose- and time-dependent manner.
  • Cell cycle arrest at G2/M phase and suppressed cyclin B1/CDC2 levels were observed.
  • Cell death occurred via paraptosis, characterized by cytoplasmic vacuoles, and was linked to upregulated p-ERK and increased ROS.

Conclusions:

  • Isorhamnetin exhibits potent anti-cancer activity against OSCC.
  • The mechanism involves inducing paraptosis, offering a novel therapeutic strategy.
  • Further research into isorhamnetin for OSCC treatment is warranted.
Keywords:
OSCC cellscytoplasmic vacuolesendoplasmic reticulumisorhamnetinmitochondriaparaptosis

More Related Videos

ROS Live Cell Imaging During Neuronal Development09:25

ROS Live Cell Imaging During Neuronal Development

Published on: February 9, 2021

4.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
8.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.6K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.9K